Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group" or the "Company") have announced the results of the Phase II, randomised, double blind, placebo controlled, dose-ranging trial of Cogane™ in unmedicated patients with early-stage Parkinson's disease ("CONFIDENT-PD"). Analysis of the headline results indicated that Cogane™ had no beneficial effects on patients' symptoms measured by the primary or secondary endpoints in the study...
More...
More...